News & Press | Microvention

Jan 12, 2021

Lower-Profile WEB Intrasaccular Aneurysm Treatment Device Receives FDA Approval

The WEB™ Aneurysm Embolization System expands with a lower profile delivery system and new size configurations.

Jan 12, 2021

Lower-Profile WEB Intrasaccular Aneurysm Treatment Device Receives FDA Approval

The WEB™ Aneurysm Embolization System expands with a lower profile delivery system and new size configurations.

Dec 23, 2020

MicroVention, Inc. Files Trade Secret Lawsuit Against Balt USA, LLC

MicroVention, Inc., a U.S. based subsidiary of Terumo and leading global neurovascular company, announced today the filing of a second lawsuit against Balt USA, LLC and four former employees for trade secret misappropriation.

Apr 21, 2020

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide

Contributions include USD 1 million to the COVID-19 Solidarity Response Fund for WHO

Mar 13, 2020

MicroVention Expands Worldwide Innovation Center

Two years after MicroVention, Inc. relocated their Worldwide Innovation Center to 35 Enterprise, the neurovascular company is expanding within the Summit Office Campus to accommodate for their rapid growth.

Jan 08, 2020

MicroVention Announces FDA Premarket Approval of a New Flow Diverter for the Treatment of Brain Aneurysms

MicroVention, Inc., a U.S. based subsidiary of Terumo and a global neurovascular company announced the FDA Premarket Approval (PMA) for the FRED® (Flow Re-Direction Endoluminal Device) device for the treatment of brain aneurysms.

Apr 24, 2019

MicroVention Announces Positive Safety and Effectiveness Results in WEB-IT Pivotal Trial Published in Journal of Neurointerventional Surgery

The WEB-IT pivotal trial highlights positive clinical outcomes with the WEB® Aneurysm Embolization System, the only intrasaccular flow disruptor approved in the United States.

Jan 07, 2019

Novel Intrasaccular Aneurysm Treatment Device Receives FDA PMA Approval

The WEB® Aneurysm Embolization System is the first intrasaccular flow disruptor PMA approved for the embolization of wide neck bifurcation aneurysms

Jun 12, 2018

MicroVention Announces FDA Clearance for Thrombectomy Device

Microvention Announces FDA Clearance for Thrombectomy Device. SOFIA® Catheter; A New Device for the Revascularization of Patients with Acute Ischemic Stroke

May 31, 2018

MicroVention® Announces FDA Approval For Neuro Stent Device

The LVIS® and LVIS® Jr. stents are the first stents PMA approved for stent-assisted coil embolization

Jan 15, 2018

MicroVention and Terumo Corporation Announce Data from Multicenter Great Study

Randomized, Controlled, 500-Patient Trial Showed Patients Treated by Hydrogel Coils Less Likely to Have Adverse Outcomes than those Treated by Standard Bare Platinum Coils; Data Presented at International Stroke Conference 2017

Sep 26, 2017

MicroVention Celebrates Grand Opening of New Worldwide Innovation Center in Aliso Viejo, California

Microvention Celebrates Grand Opening of New Worldwide Innovation Center in Aliso Viejo, California and also Celebrates 20th Anniversary in New 205,000 Square-Foot Facility

Jun 20, 2017

Orange Country Business Journal Article On MicroVention

Maker of Tiny Devices Goes Big With New Base

Jul 14, 2016

Terumo Corporation Completes Acquisition of Sequent Medical

Unique Aneurysm Embolization Device Complements MicroVention’s Neurovascular Product Portfolio

Jun 15, 2016

Terumo Corporation Acquires Sequent Medical

MicroVention Gains Developer of New Aneurysm Embolization Device

Jun 14, 2016

Terumo Acquires Sequent Medical, U.S.-based Developer of New Aneurysm Embolization Device

Sep 20, 2015

MicroVention Goes Back to Its Roots

Back to Its Roots: Neurovascular company to come home to much bigger house

Jun 01, 2015

MicroVention to Locate Its New 205,000 Square-Foot Worldwide Headquarters At Summit Office Campus in Aliso Viejo

Groundbreaking Ceremony to be Held June 4, 2015; Occupancy Expected First Half of 2017

Jul 22, 2013

FRED First U.S. Case

MicroVention Announces First Trial Enrollment In Their U.S. Clinical Trial of Its New Dual-Layer Stent For Cerebral Aneurysm Flow Diversion

Mar 06, 2013

MicroVention Costa Rica Plant Opening

MicroVention’s New Manufacturing Plant Facility In Costa Rica Celebrates Grand Opening With Inaugural Plant Ceremony

Jul 02, 2012

HEAT Trial

MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms

Aug 03, 2010

Final Data In International Trial Supports Safety and Effectiveness of MicroVention-Terumo’s HydroCoil® Embolic System for Treatment of Cerebral Aneurysms

Statistically Significant Angiographic Results Show the HydroCoil Embolization System Reduces Major Recurrence Rates in 500-Patient, International Clinical Trial

Aneurysm Therapy

Ischemic Stroke and Carotid Artery Disease

Neurovascular Malformations

Access Product Solutions

Lower-Profile WEB Intrasaccular Aneurysm Treatment Device Receives FDA Approval

Lower-Profile WEB Intrasaccular Aneurysm Treatment Device Receives FDA Approval

MicroVention, Inc. Files Trade Secret Lawsuit Against Balt USA, LLC

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide

MicroVention Expands Worldwide Innovation Center

MicroVention Announces FDA Premarket Approval of a New Flow Diverter for the Treatment of Brain Aneurysms

MicroVention Announces Positive Safety and Effectiveness Results in WEB-IT Pivotal Trial Published in Journal of Neurointerventional Surgery

Novel Intrasaccular Aneurysm Treatment Device Receives FDA PMA Approval

MicroVention Announces FDA Clearance for Thrombectomy Device

MicroVention® Announces FDA Approval For Neuro Stent Device

MicroVention and Terumo Corporation Announce Data from Multicenter Great Study

MicroVention Celebrates Grand Opening of New Worldwide Innovation Center in Aliso Viejo, California

Orange Country Business Journal Article On MicroVention

Terumo Corporation Completes Acquisition of Sequent Medical

Terumo Corporation Acquires Sequent Medical

Terumo Acquires Sequent Medical, U.S.-based Developer of New Aneurysm Embolization Device

MicroVention Goes Back to Its Roots

MicroVention to Locate Its New 205,000 Square-Foot Worldwide Headquarters At Summit Office Campus in Aliso Viejo

FRED First U.S. Case

MicroVention Costa Rica Plant Opening

HEAT Trial

Final Data In International Trial Supports Safety and Effectiveness of MicroVention-Terumo’s HydroCoil® Embolic System for Treatment of Cerebral Aneurysms